In yesterday’s Wall Street session, Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) shares traded at $16.11, down -1.41% from the previous session.
16 analysts cover Fresenius Medical Care AG & Co. KGaA (NYSE:FMS), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $25.50 and a low of $8.44, we find $15.61. Given the previous closing price of $16.34, this indicates a potential downside of -4.47 percent. FMS stock price is now 6.37% away from the 50-day moving average and -26.14% away from the 200-day moving average. The market capitalization of the company currently stands at $9.43B.
The stock has received a hold rating from 9 analysts and a buy rating from 2. Brokers who have rated the stock have averaged $15.51 as their price target over the next twelve months.
With the price target reduced from $14 to $11.70, Jefferies Downgraded its rating from Buy to Underperform for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)., while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’.
There have been several recent changes in the stakes of large investors in FMS stock. A new stake in Fresenius Medical Care AG & Co. KGaA shares was purchased by BALYASNY ASSET MANAGEMENT LLC during the first quarter worth $2,533,000. TWINBEECH CAPITAL LP invested $1,996,000 in shares of FMS during the first quarter. In the first quarter, D. E. SHAW & CO., INC. acquired a new stake in Fresenius Medical Care AG & Co. KGaA valued at approximately $1,934,000. CAMPBELL & CO INVESTMENT ADVISER LLC acquired a new stake in FMS for approximately $1,487,000. ERGOTELES LLC purchased a new stake in FMS valued at around $1,123,000 in the second quarter. In total, there are 182 active investors with 6.88% ownership of the company’s stock.
On Tuesday morning Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) stock kicked off with the opening price of $15.89. During the past 12 months, Fresenius Medical Care AG & Co. KGaA has had a low of $12.78 and a high of $35.04. The fifty day moving average price for FMS is $15.15 and a two-hundred day moving average price translates $21.81 for the stock.
The latest earnings results from Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) was released for Jun, 2022. According to the Medical Care Facilities Company, earnings per share came in at $0.37, missing analysts’ expectations of $0.42 by -0.05. This compares to $0.67 EPS in the same period last year. The company reported revenue of $5.13 billion for the quarter, compared to $5.24 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.99 percent. For the current quarter, analysts expect FMS to generate $4.55B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 05/27/2022. Investors who held shares on 05/16/2022 were paid a $0.708547 dividend. On an annualized basis, this represents a $0.71 dividend and a 4.40% percent yield. There was an ex-dividend date of 05/13/2022 for this dividend.
Fresenius Medical Care AG & Co. KGaA(FMS) Company Profile
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.